{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:52:04Z","timestamp":1782996724408,"version":"3.54.5"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Proteolysis-targeting chimeras (PROTACs) have become a game-changing mode of therapeutic\nintervention capable of turning off disease-driving proteins by using the ubiquitinproteasome\nsystem. In contrast to conventional inhibitors, PROTACs act through event-driven\npharmacology and, by providing comprehensive clearance of targeted proteins, they promise to address\nresistance mechanisms that plague conventional therapies. This review discusses the paradigm-\nshifting potential of PROTACs to degrade poly (ADP-ribose) polymerases (PARPs), key regulatory\nenzymes in the DNA damage response whose inhibition has been clinically validated in\nBRCA-mutant cancers. Nevertheless, resistance to PARP inhibitors has led to the need for alternative\napproaches, and PROTACs have become a potent strategy to degrade PARP via the proteasome.\nA key component of this strategy is Cereblon (CRBN), which is a commonly utilized E3\nligase in the design of PROTACs and is considered highly druggable and expressed. We unravel the\nmolecular actions that are the basis of CRBN-directed protein degradation and address the existing\nissues, such as ligase saturation, resistance through mutations, and off-target signatures, as well as\ntranslational challenges of PROTAC technology, such as pharmacokinetics, cell permeability, and\npotential toxicity. Moreover, we demonstrate emerging technologies such as dual-ligase PROTACs,\nAI-based ligand optimization, and deep mutational scanning as methods to enhance degrader space\nand target efficacy. This review combines insights on the mechanisms with upcoming technologies\nto propose important prospects and future research gaps in E3 ligase selection, degrader specificity,\nand resistance management. Together, we introduce PARP-targeting PROTACs, in collaboration\nwith CRBN, as a promising area of precision drug development and oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113895575441629260617065327","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:41:41Z","timestamp":1782996101000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PROTAC-Mediated Targeting of PARP via CRBN: Mechanistic Insights, Resistance Challenges, and Therapeutic Advancements"],"prefix":"10.2174","volume":"26","author":[{"given":"Hannah Lalengzuali","family":"Fanai","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education &amp; Research, Ooty, The Nilgiris, Tamil Nadu 643001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basuvan","family":"Babu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, JSS College of Pharmacy, JSS Academy of Higher Education &amp; Research, Ooty, The Nilgiris, Tamil Nadu 643001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalirajan","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education &amp; Research, Ooty, The Nilgiris, Tamil Nadu 643001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-7464","authenticated-orcid":true,"given":"Gowramma","family":"Byran","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education &amp; Research, Ooty, The Nilgiris, Tamil Nadu 643001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575441629260617065327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/255701\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575441629260617065327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:42:05Z","timestamp":1782996125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/255701\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113895575441629260617065327","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}